Citadel Advisors
FNCH

Citadel Advisors’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Citadel Advisors’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-826
Closed -$70K – 14013
2022
Q2 		$70K Sell
826
-1,165
-59% -$99.6K ﹤0.01% 11710
2022
Q1 		$300K Sell
1,991
-586
-23% -$135K ﹤0.01% 10599
2021
Q4 		$771K Buy
+2,577
New +$988K ﹤0.01% 8580

Other funds holding FNCH

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
TA
TRB Advisors New York $146M AUM 3.71% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors's FNCH Position: Q3 2022 in Review

Citadel Advisors sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q3 2022, closing a stake of 826 shares — an estimated $70K sold.

Citadel Advisors first reported a position in FNCH in Q4 2021 and held it in 3 quarters. The position peaked at $771K in Q4 2021. 43 funds tracked by Wall St. Rank hold FNCH as of Q3 2022.

  • Citadel Advisors reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 826 Finch Therapeutics Group, Inc. Common Stock shares in Q3 2022, an estimated $70K.
  • Citadel Advisors first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Citadel Advisors's Finch Therapeutics Group, Inc. Common Stock position peaked at $771K in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.